Squarepoint Ops LLC Has $517,000 Stake in Twist Bioscience Co. (NASDAQ:TWST)

Squarepoint Ops LLC lowered its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 93.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,491 shares of the company's stock after selling 147,925 shares during the period. Squarepoint Ops LLC's holdings in Twist Bioscience were worth $517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the second quarter worth about $61,000. Nisa Investment Advisors LLC raised its position in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock valued at $113,000 after purchasing an additional 546 shares during the period. Finally, CWM LLC increased its position in shares of Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company's stock worth $120,000 after acquiring an additional 524 shares during the last quarter.

Twist Bioscience Stock Up 0.5 %

Shares of NASDAQ:TWST traded up $0.20 during midday trading on Thursday, reaching $41.65. The company's stock had a trading volume of 618,035 shares, compared to its average volume of 975,271. The stock has a fifty day moving average of $44.08 and a 200 day moving average of $43.83. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90. The firm has a market capitalization of $2.43 billion, a PE ratio of -12.34 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to analysts' expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company's quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.01) earnings per share. Sell-side analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several analyst reports. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. TD Cowen boosted their target price on Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, June 13th. The Goldman Sachs Group raised their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, July 9th. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Finally, Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $51.63.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 709 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now directly owns 78,996 shares in the company, valued at approximately $3,154,310.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Paula Green sold 1,137 shares of the business's stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the transaction, the senior vice president now directly owns 88,837 shares of the company's stock, valued at $3,547,261.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 709 shares of the company's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares of the company's stock, valued at approximately $3,154,310.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,390 shares of company stock valued at $1,793,567 in the last three months. Corporate insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.